UNIKUM Therapeutics was spun out from the Department of Biomedicine at Aarhus University in 2020. It’s founded on the breakthrough discovery on how to manufacture a specific type of innate immune cell named plasmacytoid Dendritic Cells (pDCs) for use in cellular therapies, including cancer immunotherapy. pDCs are multifaceted immune cells with features that have been lacking in existing therapies. UNIKUM Therapeutics has developed methods to genetically engineer the cells, thereby further enhancing their therapeutic potential and establishing a unique position to champion a whole new class of cellular therapies. The company is funded by the Creation House program at the BioInnovation Institute and the Innobooster program from the Innovation Fund Denmark.
Established in 2020.